Risk factor
Resilient to price shocks
Profitability factor
Greatly undervalued vs peers
About
Dong-A Socio Holdings Co., Ltd. engages in the pharmaceutical business in South Korea and internationally. It offers Bacchus, Benachio, and Tempo; infection management products; imaging equipment, such as FX-V1 and CLS-S7 for surgery and diagnosis; and MEDIFLIX, a medical knowledge-sharing platform. The company provides business management services; CMO services, including pre-clinical study, clinical trial, and commercial production of antibodies and recombinant proteins; maintenance, repair, and operation; quarantine; and military logistics services; and packaging and parcel delivery services. In addition, it offers mineral water under the Gayasan Cheonnyeonsu brand; POCARI SWEAT; Narangd cider; Oronamin C; Oran-C bio-PET; and STP2104, an mRNA based COVID-19 vaccine, which is in phase I clinical trial. Further, the company engages in the construction of industrial facilities, such as bio, pharmaceutical, food, logistics warehouses, education/research facilities, work/sales facilities, and public facilities; provides design, maintenance, and asset development services. Additionally, it provides IT systems development and maintenance. The company was founded in 1932 and is headquartered in Seoul, South Korea.
Company Valuation
Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers. In particular, the stock is underpriced on P/E, 'cheap' on EV/EBIT
Target Price
The average target price of 000640.KS is 148673 and suggests 58% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to
Buy
Sell